BUSINESS

• Opdivo Significantly Prolongs OS in Gastric Cancer Patients in PIII Study: Ono
  November 11, 2016

• Takecab Most Promoted Drug in September: Anterio
  November 11, 2016

• Top 4 Wholesalers See Lower Sales in April-September If Hep C Meds Excluded
  November 11, 2016

• Enrollment Completed for PIII Adcetris Study for Mature T-Cell Lymphoma: Takeda
  November 10, 2016

• Nippon Shinyaku’s DMD Med Gets Fast Track Status in US
  November 10, 2016

• Kipres Generics Earn Bronchial Asthma Indication in Droves
  November 10, 2016

• MSD to Seek Keytruda Listing after Adding Lung Cancer Indication
  November 10, 2016

• Takeda to Collaborate with 2 Universities on Application of Miniature Liver Technology to Drug Discovery Research
  November 10, 2016

• Kipres AG’s Market Penetration Faster than Expected: Kyorin President
  November 9, 2016

• Teva Takeda Pharma “Not a Threat” at Present: Nichi-Iko Pres. Tamura
  November 9, 2016

• BIKEN, Mitsubishi Tanabe to Form Vaccine JV Next May
  November 8, 2016

• Current Drug Pricing System Became Unfit for New Drugs Like Opdivo: Ono Chief
  November 8, 2016

• Ono's Revenue and Profits Soar as Opdivo Sales Jump 1,714%
  November 8, 2016

• MSD’s New Dual Oral Hep C Therapy to Challenge Harvoni; Effective Regardless of Resistance Mutations, Renal Impairment
  November 8, 2016

• Japan Diabetes Market Likely to Grow 40% by 2024: Fuji Keizai
  November 7, 2016

• Eisai’s Halaven Clinches NICE OK as 3rd-Line Breast Cancer Therapy
  November 7, 2016

• Mitsubishi Tanabe to Offer Compound Library to Univ. of Tokyo
  November 7, 2016

• Acne Med Epiduo Gel Hits Japan Shelves: Maruho
  November 7, 2016

• JCR to Provide Temcell for IIT in Epidermolysis Bullosa
  November 4, 2016

• Santen Profits Tumble Over 70% on Strong Yen, Divestment; Ophthalmology Biz Brisk
  November 4, 2016

ページ

• « 先頭
• ‹ Prev
• …
• 451
• 452
• 453
• 454
• 455
• 456
• 457
• 458
• 459
• …
• Next ›
• 最終 »